用人工智能驱动的多式联络数据融合,用于对阿尔茨海默病生物标志物进行评估
Varuna H Jasodanand1, Sahana S Kowshik1,2, Shreyas Puducheri1
1Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Nature communications
|August 11, 2025
概括
这项研究引入了一种计算方法来预测阿尔茨海默病的生物标志物,粉样蛋白β和,使用常见的神经测试而不是昂贵的PET扫描. 这为临床试验和患者查提供了可扩展的方法.
科学领域:
- 神经学 神经学
- 计算生物学 计算生物学
- 生物标志物发现发现
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于检测粉样β (Aβ) 斑块和神经纤维 tau (τ) .
- 定子发射断层扫描 (PET) 图像是Aβ和 τ检测的标准,但成本昂贵,无法广泛临床使用.
研究的目的:
- 开发和验证一个多式联络计算框架,以使用随时可用的神经评估来估计单个PET配置文件.
- 为AD生物标志物评估提供直接PET成像的可扩展和实用的替代方案.
主要方法:
- 整合了来自七个不同的队列 (12,185名参与者) 的数据.
- 开发一个计算模型,从神经评估中预测Aβ和 τ状态.
- 根据生物标志物概况,死后病理和已知的tau沉积模式进行验证.
主要成果:
- 该框架实现了接收器运行特征曲线 (AUROC) 下的面积为Aβ分类的0.79和 τ分类的0.84.
- 预测的PET状态与各种生物标志物概况和死后发现一致.
- 模型识别的区域大脑体积与tau沉积的既定空间模式相关联.
结论:
- 开发的计算框架提供了一种有希望的,具有成本效益的方法来估计Aβ和 τ状态.
- 这种方法可以促进针对抗粉样蛋白治疗和临床试验的候选人的可扩展的预选.
- 这项研究为直接PET成像提供了一个切实可行的替代方案,有可能提高AD诊断的可访问性.
相关概念视频
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261


